Insider Selling: Edwards Lifesciences (NYSE:EW) Insider Sells $698,637.00 in Stock

Edwards Lifesciences Corporation (NYSE:EW) insider Larry Wood sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Edwards Lifesciences Stock Performance

NYSE EW opened at $81.2740 on Thursday. The stock has a market capitalization of $47.72 billion, a PE ratio of 11.69, a P/E/G ratio of 3.81 and a beta of 1.08. The business has a 50 day simple moving average of $77.35 and a two-hundred day simple moving average of $74.54. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently modified their holdings of the business. Rosenberg Matthew Hamilton bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $28,000. Vega Investment Solutions bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $27,000. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $26,000. NewSquare Capital LLC lifted its stake in shares of Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares during the last quarter. Finally, SouthState Corp bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $27,000. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

EW has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft raised their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a report on Friday, July 25th. William Blair raised Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. Truist Financial raised their price objective on Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a research note on Friday, July 25th. Royal Bank Of Canada raised their price objective on Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.90.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.